Expert Opinions and Consensus Recommendations for the Evaluation and Management of Insomnia in Clinical Practice: Joint Statements of Five Italian Scientific Societies.
clinical practice
consensus recommendations
evaluation
expert opinions
insomnia
treatment
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2020
2020
Historique:
received:
19
02
2020
accepted:
01
06
2020
entrez:
17
7
2020
pubmed:
17
7
2020
medline:
17
7
2020
Statut:
epublish
Résumé
Insomnia is the most commonly reported sleep problem in industrialized countries worldwide being present in about 36.8% of the general population. In Italy, such a percentage seems to be even higher. Although insomnia can be an independent disorder, it is most frequently observed as a comorbid condition and may precipitate, exacerbate, or prolong a broad range of comorbid conditions including physical and mental illnesses. Evaluating and targeting insomnia in the Italian clinical practice should be a priority. The present expert options and recommendations development process was based on the RAND/UCLA Appropriateness Method for conceptualizing, designing, and carrying out the appropriateness of procedures for the diagnosis and treatment. Only available options in Italy were taken into considerations. We evaluated 12 international guidelines and 12 most recent systematic reviews for insomnia evaluation and treatment produced in the last 10 years. Our findings suggested that symptoms of insomnia must always be assessed in the Italian clinical practice by evaluating nocturnal and daytime symptoms, comorbid conditions and lifestyle. In a patient with chronic insomnia with and without comorbidity, insomnia treatment should be always initiated. CBT-Insomnia therapy should be the first option accordingly to availability. The choice of the drug should be based on different factors such as type of insomnia, age, comorbidities, and potential side effects. Melatonin 2 mg prolonged release should be the first choice in subjects >55 years. If the choice would be a Z-drug or a short-acting benzodiazepine (in subjects <65 years old) or a sedating antidepressant, the use should be in the short term (≤4 weeks) and then proceeds to tapering under clinical monitoring.
Sections du résumé
BACKGROUND
BACKGROUND
Insomnia is the most commonly reported sleep problem in industrialized countries worldwide being present in about 36.8% of the general population. In Italy, such a percentage seems to be even higher. Although insomnia can be an independent disorder, it is most frequently observed as a comorbid condition and may precipitate, exacerbate, or prolong a broad range of comorbid conditions including physical and mental illnesses. Evaluating and targeting insomnia in the Italian clinical practice should be a priority.
METHODS
METHODS
The present expert options and recommendations development process was based on the RAND/UCLA Appropriateness Method for conceptualizing, designing, and carrying out the appropriateness of procedures for the diagnosis and treatment. Only available options in Italy were taken into considerations.
RESULTS
RESULTS
We evaluated 12 international guidelines and 12 most recent systematic reviews for insomnia evaluation and treatment produced in the last 10 years.
CONCLUSIONS
CONCLUSIONS
Our findings suggested that symptoms of insomnia must always be assessed in the Italian clinical practice by evaluating nocturnal and daytime symptoms, comorbid conditions and lifestyle. In a patient with chronic insomnia with and without comorbidity, insomnia treatment should be always initiated. CBT-Insomnia therapy should be the first option accordingly to availability. The choice of the drug should be based on different factors such as type of insomnia, age, comorbidities, and potential side effects. Melatonin 2 mg prolonged release should be the first choice in subjects >55 years. If the choice would be a Z-drug or a short-acting benzodiazepine (in subjects <65 years old) or a sedating antidepressant, the use should be in the short term (≤4 weeks) and then proceeds to tapering under clinical monitoring.
Identifiants
pubmed: 32670104
doi: 10.3389/fpsyt.2020.00558
pmc: PMC7332855
doi:
Types de publication
Systematic Review
Langues
eng
Pagination
558Informations de copyright
Copyright © 2020 Palagini, Manni, Aguglia, Amore, Brugnoli, Girardi, Grassi, Mencacci, Plazzi, Minervino, Nobili and Biggio.
Références
Sleep Med Rev. 2017 Jun;33:51-57
pubmed: 27321864
Curr Opin Psychiatry. 2018 May;31(3):176-182
pubmed: 29537983
Compr Psychiatry. 2019 Feb;89:46-51
pubmed: 30593973
Int J Psychophysiol. 2015 Dec;98(3 Pt 1):435-40
pubmed: 26344179
Chest. 2017 Aug;152(2):435-444
pubmed: 28153671
J Sleep Res. 2019 Dec;28(6):e12841
pubmed: 30968511
Sleep Med. 2004 Jan;5(1):67-75
pubmed: 14725829
Front Neuroendocrinol. 2019 Jan;52:22-28
pubmed: 29908879
Neurol Sci. 2016 Sep;37(9):1517-24
pubmed: 27234459
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Sleep. 2014 Nov 01;37(11):1787-98
pubmed: 25364074
J Psychopharmacol. 2019 Aug;33(8):923-947
pubmed: 31271339
Behav Sleep Med. 2017 Mar-Apr;15(2):144-157
pubmed: 26745754
Drugs Aging. 2009 Dec;26 Suppl 1:15-30
pubmed: 20136166
Sleep Med. 2002 Mar;3(2):115-20
pubmed: 14592229
Curr Med Res Opin. 2005 Nov;21(11):1785-92
pubmed: 16307699
Duodecim. 2016;132(3):277-8
pubmed: 26951032
Innov Clin Neurosci. 2017 Aug 01;14(7-8):24-34
pubmed: 29552421
Int J Clin Pract. 2013 Dec;67(12):1311-6
pubmed: 24246209
J Sleep Res. 1999 Dec;8(4):319-20
pubmed: 10646173
Clin Med (Lond). 2011 Jun;11(3):278-81
pubmed: 21902086
Clin Drug Investig. 2005;25(12):745-64
pubmed: 17532721
Behav Res Ther. 1985;23(3):263-71
pubmed: 4004706
Sleep Med. 2014 Feb;15(2):173-9
pubmed: 24382513
Curr Psychiatry Rep. 2017 Aug;19(8):44
pubmed: 28616860
J Psychiatr Res. 2012 Oct;46(10):1278-85
pubmed: 22800714
Pharmacol Rev. 2018 Apr;70(2):197-245
pubmed: 29487083
Expert Opin Pharmacother. 2012 Aug;13(12):1707-17
pubmed: 22712761
J Clin Sleep Med. 2017 Feb 15;13(2):275-281
pubmed: 27855744
Lancet Neurol. 2014 Oct;13(10):1017-28
pubmed: 25231524
Sleep Med Rev. 2010 Dec;14(6):379-89
pubmed: 20359916
J Sleep Res. 2000 Mar;9(1):35-42
pubmed: 10733687
Curr Pharm Des. 2013;19(13):2409-19
pubmed: 23173590
Curr Opin Pulm Med. 2018 Nov;24(6):543-548
pubmed: 30148726
Br J Psychiatry. 1997 Feb;170:176-80
pubmed: 9093510
Ann Intern Med. 2016 Jul 19;165(2):125-33
pubmed: 27136449
Cochrane Database Syst Rev. 2014 Mar 21;(3):CD009178
pubmed: 24659320
Sleep Med Rev. 2018 Feb;37:105-113
pubmed: 28363449
Curr Psychiatry Rep. 2013 Dec;15(12):418
pubmed: 24189774
Encephale. 2017 Aug;43(4):363-373
pubmed: 27669996
BMJ Open. 2014 Mar 18;4(3):e004183
pubmed: 24643168
Encephale. 2018 Dec;44(6):548-557
pubmed: 30107892
J Sleep Res. 2017 Dec;26(6):675-700
pubmed: 28875581
J Sleep Res. 2014 Apr;23(2):143-52
pubmed: 24237855
Behav Res Ther. 2002 Aug;40(8):869-93
pubmed: 12186352
Lancet. 2012 Mar 24;379(9821):1129-41
pubmed: 22265700
J Clin Sleep Med. 2011 Dec 15;7(6):645-52
pubmed: 22171204
Sleep. 2012 Feb 01;35(2):287-302
pubmed: 22294820
Sleep. 1991 Dec;14(6):540-5
pubmed: 1798888
Sleep Med Rev. 2012 Dec;16(6):547-59
pubmed: 22401983
J Sleep Res. 2020 Apr;29(2):e12967
pubmed: 31856367
Sleep Med Rev. 2017 Aug;34:10-22
pubmed: 28648359
J Psychopharmacol. 2010 Nov;24(11):1577-601
pubmed: 20813762
Hum Psychopharmacol. 2012 May;27(3):270-6
pubmed: 22350925
Cochrane Database Syst Rev. 2018 May 14;5:CD010753
pubmed: 29761479
Expert Opin Pharmacother. 2018 Sep;19(13):1465-1473
pubmed: 30175928
J Clin Sleep Med. 2017 Feb 15;13(2):307-349
pubmed: 27998379
Sleep Med Rev. 2010 Feb;14(1):19-31
pubmed: 19481481
Psychiatr Clin North Am. 1987 Dec;10(4):541-53
pubmed: 3332317
J Clin Psychiatry. 2012 Sep;73(9):e1160-7
pubmed: 23059158
Sleep Med Rev. 2019 Feb;43:96-105
pubmed: 30537570
Encephale. 2019 Nov;45(5):413-423
pubmed: 31248601